Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07230730 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria revised
    • Secondary endpoints revised (24)
    • Primary endpoints revised (2)
    v4
  2. Eligibility criteria revisedv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2025 to Jan 13, 2026
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is being conducted to evaluate the efficacy, and safety of SHR-1918 in reducing serum low-density lipoprotein cholesterol (LDL-C) and total triglycerides (TG) in patients with hyperlipidemia compared with placebo, and also includes To evaluate the effectiveness of SHR-1918 in reducing other lipid indicators in patients with mixed hyperlipidemia and to assess the safety of SHR-1918 in patients with mixed hyperlipidemia.
Trial Details
NCT Number NCT07230730
Lead Sponsor Beijing Suncadia Pharmaceuticals Co., Ltd
Conditions
(from sponsor)		 Hyperlipidemia
Related terms Hyperlipidemias
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov